Eloxx Q2 Loss Widens to $4.5M; Cash Runway Extended to Mid-2028 After $66M Raise

summarizeSummary

Eloxx Pharmaceuticals reported a Q2 2026 net loss of $4.5 million, up from $1.9 million a year ago, as it ramps up R&D for exaluren. With $62 million in cash after a $66 million raise, the company has runway into mid-2028, past key data readouts for Alport syndrome and ADPKD.

check_boxKey Events · Earnings and Guidance · ELOX

• Q2 Loss Widens on Higher R&D

  Net loss of $4.5 million ($0.39/share) vs $1.9 million ($5.45/share) in Q2 2025, driven by increased clinical trial expenses for exaluren.

• Cash Runway Extended to Mid-2028

  Cash and equivalents of $62.0 million as of June 30, 2026, after a $66.0 million public offering and Nasdaq uplisting, expected to fund operations through key data readouts.

• Phase 2b Alport Trial to Start Q3 2026

  FDA clearance received; trial initiation expected this quarter with topline data from the 16-week placebo-controlled portion by mid-2027 and final readout by end of 2027.

• Orphan Designation in Europe for ADPKD

  European Commission granted orphan medicinal product designation for exaluren in ADPKD; Phase 2 trial planned for 2027 with topline data by mid-2028.

auto_awesomeAnalysis · ELOX · Life Sciences

A net loss of $4.5 million for Q2 2026, up from $1.9 million a year ago, reflects higher R&D spending as exaluren advances. The company ended June with $62 million in cash following a $66 million public offering and Nasdaq uplisting, extending its runway into mid-2028 — past key data readouts for both Alport syndrome and ADPKD. The Phase 2b trial in nonsense mutation Alport syndrome is set to start this quarter, with topline data expected by mid-2027. Orphan drug designation in Europe for ADPKD adds regulatory momentum. The strengthened board and debt-free balance sheet position the company to execute on its clinical milestones, though the widening loss and material weakness in controls remain concerns.